For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...

In the past few weeks, some of the world’s biggest soda, snack and candy companies reported quarterly earnings, so this week we’re introducing ad tech to a new three-letter acronym – GLP-1. Even if ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...